Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ITCI Intra-Cellular Therapies	$131.87	$131.84	$64.72 ▼ $131.98	$14.05B	0.69	1.52 million shs	N/A
SMMT Summit Therapeutics	$25.85 +0.3%	$23.00	$2.10 ▼ $36.91	$19.20B	-0.94	3.90 million shs	1.76 million shs
TEVA Teva Pharmaceutical Industries	$16.95 +0.0%	$15.38	$12.47 ▼ $22.80	$19.21B	0.62	9.98 million shs	6.48 million shs
TGTX TG Therapeutics	$34.57 +1.0%	$38.13	$15.16 ▼ $46.48	$5.49B	2.21	2.98 million shs	1.04 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ITCI Intra-Cellular Therapies	0.00%	0.00%	0.00%	+2.54%	+95.94%
SMMT Summit Therapeutics	+0.31%	+8.29%	-22.31%	+16.86%	+488.84%
TEVA Teva Pharmaceutical Industries	+0.03%	-0.02%	+18.50%	+1.19%	+0.33%
TGTX TG Therapeutics	+0.96%	+0.61%	-12.58%	+11.95%	+95.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ITCI Intra-Cellular Therapies	0.6714 of 5 stars	1.1	0.0	0.0	4.5	0.0	1.7	0.6
SMMT Summit Therapeutics	3.0356 of 5 stars	4.5	2.0	0.0	0.0	3.7	1.7	0.0
TEVA Teva Pharmaceutical Industries	3.2951 of 5 stars	3.6	5.0	0.8	0.0	3.4	0.8	0.6
TGTX TG Therapeutics	3.8019 of 5 stars	2.4	2.0	0.0	3.5	3.7	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ITCI Intra-Cellular Therapies	2.17	Hold	$109.70	-16.81% Downside
SMMT Summit Therapeutics	3.09	Buy	$37.40	44.68% Upside
TEVA Teva Pharmaceutical Industries	3.13	Buy	$24.43	44.16% Upside
TGTX TG Therapeutics	2.80	Moderate Buy	$40.80	18.02% Upside

Current Analyst Ratings Breakdown

Latest TGTX, TEVA, SMMT, and ITCI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/12/2025	TEVA Teva Pharmaceutical Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$21.00 ➝ $23.00
5/8/2025	SMMT Summit Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	TEVA Teva Pharmaceutical Industries	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
5/2/2025	SMMT Summit Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $41.00
4/28/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
4/28/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00 ➝ $40.00
4/28/2025	TEVA Teva Pharmaceutical Industries	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/25/2025	SMMT Summit Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$31.00 ➝ $44.00
4/23/2025	SMMT Summit Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
4/2/2025	ITCI Intra-Cellular Therapies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$132.00 ➝ $132.00
3/26/2025	SMMT Summit Therapeutics	Summit Redstone Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$35.00

(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ITCI Intra-Cellular Therapies	$680.50M	20.64	N/A	N/A	$6.15 per share	21.44
SMMT Summit Therapeutics	$700K	27,425.59	N/A	N/A	$0.11 per share	235.00
TEVA Teva Pharmaceutical Industries	$16.62B	1.16	$3.36 per share	5.05	$4.75 per share	3.57
TGTX TG Therapeutics	$386.39M	14.20	$0.10 per share	353.90	$1.06 per share	32.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	694.05	N/A	-14.07%	-9.93%	-8.38%	N/A
SMMT Summit Therapeutics	-$614.93M	-$0.34	N/A	N/A	N/A	N/A	-85.42%	-52.66%	8/5/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.44	1.44	-9.91%	42.46%	6.65%	7/30/2025 (Estimated)
TGTX TG Therapeutics	$12.67M	$0.24	N/A	34.57	N/A	-5.42%	-8.32%	-3.40%	8/5/2025 (Estimated)

Latest TGTX, TEVA, SMMT, and ITCI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
5/7/2025	Q1 2025	TGTX TG Therapeutics	$0.19	$0.03	-$0.16	$0.03	$117.07 million	$120.86 million
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
3/3/2025	Q4 2024	TGTX TG Therapeutics	$0.08	$0.15	+$0.07	$0.15	$100.67 million	$108.19 million
2/24/2025	Q4 2024	SMMT Summit Therapeutics	-$0.08	-$0.08	N/A	-$0.08	N/A	$0.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.01	5.97%	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
SMMT Summit Therapeutics	N/A	8.31	8.31
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75
TGTX TG Therapeutics	1.27	4.59	3.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ITCI Intra-Cellular Therapies	92.33%
SMMT Summit Therapeutics	4.61%
TEVA Teva Pharmaceutical Industries	54.05%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
ITCI Intra-Cellular Therapies	2.60%
SMMT Summit Therapeutics	84.90%
TEVA Teva Pharmaceutical Industries	0.49%
TGTX TG Therapeutics	10.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ITCI Intra-Cellular Therapies	560	106.52 million	103.56 million	Optionable
SMMT Summit Therapeutics	110	742.67 million	86.28 million	Optionable
TEVA Teva Pharmaceutical Industries	36,800	1.13 billion	1.13 billion	Optionable
TGTX TG Therapeutics	290	158.76 million	139.32 million	Optionable

TGTX, TEVA, SMMT, and ITCI Headlines

Recent News About These Companies

Captrust Financial Advisors Sells 22,765 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

May 24 at 3:37 AM | marketbeat.com

Castleark Management LLC Increases Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

May 23 at 8:01 AM | marketbeat.com

Deutsche Bank AG Has $4.43 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

May 22 at 3:53 AM | marketbeat.com

Soleus Capital Management L.P. Has $80.71 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

May 21 at 8:13 AM | marketbeat.com

Wexford Capital LP Invests $421,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)

May 21 at 7:06 AM | marketbeat.com

Nuveen Asset Management LLC Has $54.15 Million Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

May 21 at 4:55 AM | marketbeat.com

Balyasny Asset Management L.P. Invests $274,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)

May 20, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by BNP Paribas Financial Markets

May 20, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of "Moderate Buy" by Brokerages

May 20, 2025 | marketbeat.com

Rafferty Asset Management LLC Trims Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

May 19, 2025 | marketbeat.com

Gotham Asset Management LLC Sells 64,333 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

May 19, 2025 | marketbeat.com

Which Is a Better Investment, BioCryst Pharmaceuticals, Inc. or TG Therapeutics, Inc. Stock?

May 18, 2025 | aaii.com

Jacobs Levy Equity Management Inc. Has $2.55 Million Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

May 18, 2025 | marketbeat.com

Nicholas Investment Partners LP Reduces Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

May 16, 2025 | marketbeat.com

J. Goldman & Co LP Cuts Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

May 15, 2025 | marketbeat.com

Integral Health Asset Management LLC Purchases Shares of 150,000 TG Therapeutics, Inc. (NASDAQ:TGTX)

May 14, 2025 | marketbeat.com

Brevan Howard Capital Management LP Takes $453,000 Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

May 12, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Algert Global LLC

May 12, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Purchased by Northern Trust Corp

May 11, 2025 | marketbeat.com

Cantor Fitzgerald Predicts TG Therapeutics FY2025 Earnings

May 10, 2025 | marketbeat.com

Q3 Earnings Forecast for TG Therapeutics Issued By B. Riley

May 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TGTX, TEVA, SMMT, and ITCI Company Descriptions

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)

As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Summit Therapeutics NASDAQ:SMMT

$25.85 +0.08 (+0.31%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$25.72 -0.14 (-0.52%)

As of 05/23/2025 07:49 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries NYSE:TEVA

$16.94 +0.01 (+0.03%)

Closing price 05/23/2025 03:59 PM Eastern

Extended Trading

$17.00 +0.05 (+0.32%)

As of 05/23/2025 07:58 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

TG Therapeutics NASDAQ:TGTX

$34.57 +0.33 (+0.96%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$34.72 +0.15 (+0.44%)

As of 05/23/2025 07:49 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time